Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 75/100

Failure Rate

20.0%

1 terminated/withdrawn out of 5 trials

Success Rate

75.0%

-11.5% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

33%

1 of 3 completed trials have results

Key Signals

1 recruiting1 with results

Enrollment Performance

Analytics

Phase 2
3(60.0%)
Phase 1
2(40.0%)
5Total
Phase 2(3)
Phase 1(2)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (5)

Showing 5 of 5 trials
NCT05460832Phase 2Completed

Phase 2b Study of MBS2320 in Participants With Methotrexate-Refractory RA

Role: lead

NCT05951296Phase 2Withdrawn

A Study to Investigate Leramistat in Patients With IPF

Role: lead

NCT06379958Phase 1Recruiting

Drug-Drug Interaction (DDI) Study of Leramistat in Healthy Adult Subjects

Role: lead

NCT03139136Phase 2Completed

Safety, Tolerability and Efficacy of MBS2320 in Patients With Rheumatoid Arthritis

Role: lead

NCT02480946Phase 1Completed

Safety and Tolerability Study of MBS2320 in Healthy Subjects and Subjects With Rheumatoid Arthritis

Role: lead

All 5 trials loaded